Difference between revisions of "Epratuzumab (LymphoCide)"
Jump to navigation
Jump to search
(Created page with "==Pre-approval references== # Advani et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. [http://onli...") |
m |
||
| Line 1: | Line 1: | ||
==Pre-approval references== | ==Pre-approval references== | ||
# Advani et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.12778/full link to original article] | # Advani et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.12778/full link to original article] | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Investigational]] | ||
| + | [[Category:Antibody medications]] | ||
| + | |||
| + | [[Category:Acute lymphocytic leukemia medications]] | ||
Revision as of 20:33, 25 October 2014
Pre-approval references
- Advani et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. link to original article